Drastic action by Schultz aims to right Teva’s ship
Teva president and chief executive Kåre Schultz is seeking to achieve cost savings of US$3 billion by the end of 2019, through significant cuts to the firm’s staff, facilities and product portfolio. David Wallace reports.
You may also be interested in...
With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.
A World Health Organization negotiating body has agreed to develop a “zero draft” of the proposed pandemic treaty for discussion at a meeting of WHO member states in February next year. But the international pharmaceutical industry has reiterated its concerns about some of the proposals being put forward.
Demand-related shortages are a relatively new problem, but the FDA maintains their tools can prevent or end them.